- Core One Labs (COOL) subsidiary Vocan Biotechnologies has entered into a collaborative research agreement with UBC
- The research involves optimizing the expression of enzymes for the production of prodrug psilocybin
- Psilocybin has shown significant therapeutic benefits to those suffering from depression, anxiety, addiction and obsessive-compulsive disorder
- Core One is a biotechnology enterprise focused on bringing psychedelic medicines to market
- Core One Labs (COOL) is up by 5.43 per cent and is currently trading at C$0.97 per share
Core One Labs (COOL) subsidiary Vocan Biotechnologies has entered into a collaborative research agreement with UBC.
The research involves optimizing the expression of enzymes for the production of prodrug psilocybin from the Psilocybe genus of mushrooms.
Psilocybin has shown significant therapeutic benefits to those suffering from depression, anxiety, addiction and obsessive-compulsive disorder.
Vocan will supply its developed technology, while UBC will express critical enzymes to enable their recombinant synthesis in a suitable bacteria host.
Bacterial development will increase the efficiency and cost-effectiveness of the process and assist Vocan scientists in the production of psilocybin using fermentation.
The partners will work out of a 10,000 square foot lab located at the Lower Mall Research Station at the university.
Joel Shacker, Core One’s CEO, commented,
“The collaboration with UBC Research Faculty enables Vocan to fast track its production method of biosynthesized psilocybin. The state-of-the-art equipment will allow for enhanced analysis of the compound, and the additional personnel exponentially increases the capacity of Vocan’s research team.”
Core One is a biotechnology enterprise focused on bringing psychedelic medicines to market.
Core One Labs (COOL) is up by 5.43 per cent and is currently trading at C$0.97 per share as of 2:00 pm ET.
